216 related articles for article (PubMed ID: 33921064)
1. Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology.
Stergiou IE; Kambas K; Poulaki A; Giannouli S; Katsila T; Dimitrakopoulou A; Vidali V; Mouchtouris V; Kloukina I; Xingi E; Pagakis SN; Probert L; Patrinos GP; Ritis K; Tzioufas AG; Voulgarelis M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921064
[TBL] [Abstract][Full Text] [Related]
2. Expression significance and potential mechanism of hypoxia-inducible factor 1 alpha in patients with myelodysplastic syndromes.
Liang HW; Luo B; Du LH; He RQ; Chen G; Peng ZG; Ma J
Cancer Med; 2019 Oct; 8(13):6021-6035. PubMed ID: 31411003
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
Tong H; Hu C; Zhuang Z; Wang L; Jin J
Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108
[TBL] [Abstract][Full Text] [Related]
4. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V
Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639
[TBL] [Abstract][Full Text] [Related]
5. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
6. Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes.
Pribyl M; Hubackova S; Moudra A; Vancurova M; Polackova H; Stopka T; Jonasova A; Bokorova R; Fuchs O; Stritesky J; Salovska B; Bartek J; Hodny Z
Mol Oncol; 2020 Oct; 14(10):2403-2419. PubMed ID: 32696549
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow.
Lévesque JP; Winkler IG; Hendy J; Williams B; Helwani F; Barbier V; Nowlan B; Nilsson SK
Stem Cells; 2007 Aug; 25(8):1954-65. PubMed ID: 17478585
[TBL] [Abstract][Full Text] [Related]
8. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow.
Pecci A; Travaglino E; Klersy C; Invernizzi R
Acta Haematol; 2003; 109(1):29-34. PubMed ID: 12486320
[TBL] [Abstract][Full Text] [Related]
10. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities.
Farha S; Asosingh K; Xu W; Sharp J; George D; Comhair S; Park M; Tang WH; Loyd JE; Theil K; Tubbs R; Hsi E; Lichtin A; Erzurum SC
Blood; 2011 Mar; 117(13):3485-93. PubMed ID: 21258008
[TBL] [Abstract][Full Text] [Related]
12. Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes.
Hayashi Y; Zhang Y; Yokota A; Yan X; Liu J; Choi K; Li B; Sashida G; Peng Y; Xu Z; Huang R; Zhang L; Freudiger GM; Wang J; Dong Y; Zhou Y; Wang J; Wu L; Bu J; Chen A; Zhao X; Sun X; Chetal K; Olsson A; Watanabe M; Romick-Rosendale LE; Harada H; Shih LY; Tse W; Bridges JP; Caligiuri MA; Huang T; Zheng Y; Witte DP; Wang QF; Qu CK; Salomonis N; Grimes HL; Nimer SD; Xiao Z; Huang G
Cancer Discov; 2018 Nov; 8(11):1438-1457. PubMed ID: 30139811
[TBL] [Abstract][Full Text] [Related]
13. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
14. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
Font P; Subirá D; Matarraz S; Benavente C; Cedena MT; Morado M; Pérez Corral A; Bellón JM; Díez-Martín JL
Cytometry B Clin Cytom; 2018 May; 94(3):527-535. PubMed ID: 28618451
[TBL] [Abstract][Full Text] [Related]
15. [Effect of Qinghuang Powder combined Chinese herbs for Pi-strengthening and Shen-reinforcing on HIF-1alpha in bone marrow mononuclear cells of myelodysplastic syndrome patients: an experimental research].
Gao F; Xu YG; Yang XH; Ma R
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Feb; 34(2):174-8. PubMed ID: 24672941
[TBL] [Abstract][Full Text] [Related]
16. Value of Quantitative assessment of Myeloid Nuclear Differentiation Antigen expression and other flow cytometric parameters in the diagnosis of Myelodysplastic syndrome.
Somasundaram V; Soni S; Chopra A; Rai S; Mahapatra M; Kumar R; Pati H
Int J Lab Hematol; 2016 Apr; 38(2):141-50. PubMed ID: 26822549
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes.
Picou F; Vignon C; Debeissat C; Lachot S; Kosmider O; Gallay N; Foucault A; Estienne MH; Ravalet N; Bene MC; Domenech J; Gyan E; Fontenay M; Herault O
Blood Adv; 2019 Dec; 3(24):4271-4279. PubMed ID: 31869414
[TBL] [Abstract][Full Text] [Related]
18. Enhanced growth of myelodysplastic colonies in hypoxic conditions.
Thompson JE; Conlon JP; Yang X; Sanchez PV; Carroll M
Exp Hematol; 2007 Jan; 35(1):21-31. PubMed ID: 17198870
[TBL] [Abstract][Full Text] [Related]
19. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome.
Schlesinger M; Silverman LR; Jiang JD; Yagi MJ; Holland JF; Bekesi JG
J Clin Lab Immunol; 1996; 48(4):149-66. PubMed ID: 9819667
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.
De Smet D; Trullemans F; Jochmans K; Renmans W; Smet L; Heylen O; Bael AM; Schots R; Leus B; De Waele M
Am J Clin Pathol; 2012 Nov; 138(5):732-43. PubMed ID: 23086775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
